<DOC>
	<DOCNO>NCT01444417</DOCNO>
	<brief_summary>The purpose study evaluate efficacy romiplostim treatment thrombocytopenia pediatric patient Immune thrombocytopenia purpura ( ITP ) measure durable platelet response .</brief_summary>
	<brief_title>Safety Efficacy Study Romiplostim Treat Immune Thrombocytopenia ( ITP ) Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Diagnosis primary ITP accord American Society Hematology ( ASH ) guideline least 6 month prior screen , regardless splenectomy status Subject must refractory prior ITP therapy , relapse least 1 prior ITP therapy , ineligible ITP therapy ; prior therapy include firstline therapy Age ≥ 1 year &lt; 18 year time provide informed consent The mean 2 platelet count take screening period must ≤ 30 x 10^9/L neither count &gt; 35 x 10^9/L A serum creatinine concentration ≤ 1.5 time laboratory normal range ( age category ) screen period Adequate liver function ; serum bilirubin ≤ 1.5 time laboratory normal range screen period ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3.0 time laboratory normal range screen period Hemoglobin &gt; 10.0 g/dL screen period Subject and/or subject 's legally acceptable representative provide informed consent prior studyspecific procedure ; subject provide assent , require Known history bone marrow stem cell disorder ; abnormal bone marrow finding typical ITP must approve Amgen subject may enrol study Known active prior malignancy except adequately treat basal cell carcinoma Known history congenital thrombocytopenia Known history hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) Known history H. pylori urea breath test stool antigen test within 6 month enrollment successfully treat evidence infection Known history systemic lupus erythematosus , evans syndrome , autoimmune neutropenia Known history antiphospholipid antibody syndrome positive lupus anticoagulant Known history disseminate intravascular coagulation , hemolytic uremic syndrome , thrombotic thrombocytopenic purpura Previous history venous thromboembolism thrombotic event Previous use romiplostim , pegylated recombinant human megakaryocyte growth development factor ( PEGrHuMGDF ) , Eltrombopag , recombinant human thrombopoietin ( rHuTPO ) platelet produce agent Rituximab ( indication ) 6mercaptopurine ( 6MP ) within 14 week screen visit , anticipate use time propose study Splenectomy within 4 week screen visit All hematopoietic growth factor include interleukin11 ( IL11 ) ( oprelvekin ) within 4 week screen visit Alkylating agent within 8 week screen visit anticipate use time propose study Vaccinations know decrease platelet count within 8 week screen visit Known hypersensitivity recombinant E coliderived product ( eg , Infergen , Neupogen , Somatropin , Actimmune ) Other criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Immune ( Idiopathic ) Thrombocytopenic Purpura</keyword>
	<keyword>Pediatric Immune ( Idiopathic ) Thrombocytopenic Purpura</keyword>
	<keyword>Immune Thrombocytopenia</keyword>
</DOC>